drug
talimogene laherparepvec
Marketedupdated 5mo agoby $AMGN AMGEN INC
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying talimogene laherparepvec
- phase2Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
- phase1Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
- phase2TVEC and Preop Radiation for Sarcoma (8 ml Dose)
- phase2Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
- phase2A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
- EP1Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer
- phase1T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
- phase2A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
News(2)
- Citing Replimune approval, experts say localized cancer meds could redefine careDelivering therapeutics directly to tumors, as in the case of Replimune’s recently approved Tudriqev and Amgen’s Imlygic, holds advantages, especially when cancer is caught early, but challenges re…biospace · 10d ago
- Replimune’s twice-rejected melanoma drug prevails in FDA adcommFollowing a pair of FDA rejections of its melanoma drug, Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of the candidate’s effectiveness.fiercebiotech · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that